Who owns Vaxcyte, Inc. (PCVX)? Elite investor 13F holders
4 tracked elite investors reported holding Vaxcyte, Inc as of 2026-09-30, including Caligan Partners, D.E. Shaw, Maverick Capital, Bridgewater Associates. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent,…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Caligan Partners | VAXCYTE INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 124533388.00 USD | 2188636.000000 | Shares | hold | Original filing |
| D.E. Shaw | VAXCYTE INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 81445522.00 USD | 1431380.000000 | Shares | reduce | Original filing |
| Maverick Capital | VAXCYTE INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 77385764.00 USD | 1360031.000000 | Shares | reduce | Original filing |
| Bridgewater Associates | VAXCYTE INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 2297451.00 USD | 40377.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | VAXCYTE INC | SHARE | 2026-09-30 | 2026-11-12 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.